Abstract 157: An Early Assessment of Hospital Readmissions Among Nonvalvular Atrial Fibrillation Treated with the New Oral Anticoagulants, Apixaban, Dabigatran, and Rivaroxaban [Session Title: Poster Session I]

Conclusion: In this early assessment, treatment with rivaroxaban vs. apixaban was associated with greater risk of all-cause or bleeding-related 1-month readmissions and higher hospital costs due to readmissions.

Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Deitelzweig, S., Bruno, A., Trocio, J., Tate, N., Lin, J., Lingohr-Smith, M. Tags: Session Title: Poster Session I Source Type: research